TREATMENT ELIGIBILITY

TREATMENT ELIGIBILITY

ARE YOUR PATIENTS ELIGIBLE FOR
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)?

Enter your patient's mutations below to see if they are eligible for TRIKAFTA.

TRIKAFTA is indicated for the treatment of patients with cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.

1.

Please check to see if the mutation was entered correctly.

Please check to see if the mutation was entered correctly.

Learn how to enter 2 or more mutations

Please see most common responsive mutations below.

Most Common Responsive Mutations1,2

Already indicated based on clinical data
F508del

or

Other indicated mutations based on in vitro data

G551D | R117H | D1152H | G85E
L206W | R347P | A455E

170 less common mutations are also eligible.

Most Common Responsive Mutations1,2

Already indicated based on clinical data
F508del

or

Other indicated mutations based on in vitro data

G551D  |  R117H  |  D1152H  |  G85E
L206W  |  R347P  |  A455E

170 less common mutations are also eligible.

Mutations were considered responsive if CFTR activity resulted in a net increase of ≥10% over baseline after adding elexacaftor/tezacaftor/ivacaftor.

 

aPresent in ≥0.6% of individuals with CF.2